Proteros establishes Board of Directors and appoints industry experts

31-Mar-2010 - Germany

Proteros GmbH announced the Formation of a Board of Directors which consists of leading experts with core competences in Life Sciences and corporate development. The Board will oversee all commercial and scientific activities and will support Proteros in its further corporate development and international expansion.

In order to accelerate its development and to continue its global expansion, Proteros has appointed board members with an impressive track record in industry. Chairman of the Board is Dr. Timm-H. Jessen, formerly with Sanofi Aventis, ex-CSO of Evotec AG and renowned representative of the life science industry. Dave Lemus, MBA, CFO of MorphoSys AG since 1998 and key driver for the growth of the company has been appointed deputy chairman. The Honorary President of the Board is Nobel Laureate Prof. Dr. Robert Huber, co-founder and active scientific advisor of Proteros. The Board’s expertise is complemented by the profound experience of Dipl.-Ing. Ingo Köhler, CEO of VISCON and renowned advisor of German Pharma, Diagnostic and Biotech companies, Dr. Berthold Hinzen, Head of Global Business Development and Licensing General Medicine of Bayer-Schering Pharma AG, and Prof. Dr. Andre Schmutte, expert for industry process optimization and Six Sigma Management Consultant.

Dr. Torsten Neuefeind, CEO and co-founder of Proteros said: “We are grateful to have such a distinguished and internationally renowned group of experts on our Board supporting the next stages of Proteros’ international development.”

Dr. Jessen emphasized: “I am very proud to chair this highly experienced top-class Board of Directors and to support the continued success of Proteros. I am convinced that Proteros will continue to become an indispensable partner for the Life Sciences industry and a global player in the pre-clinical drug discovery market.”

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances